Nanotechnology for cell specific drug delivery in the liver
Hosted by Anabel Fernandez-Iglesias
With the participation of Victoria Cogger and Jordi Gracia-Sancho in the Q&A
Dr Nicholas J. Hunt is a Lecturer and postdoctoral researcher at the University of Sydney and ANZAC Research Institute at Concord Hospital in Sydney, Australia. We work on the development of nanomedicines for the targeted delivery of therapeutic agents for metabolic disease. We chemically synthesis quantum dots and nanoparticles, characterize their properties and engineer nano-structures that alter their applications within in vivo models of metabolic disease. We then examine the pharmacokinetic and dynamic properties of drug molecules we can transport with our created nanotechnology.
He completed his BSc and PhD at the University of Sydney in 2016. His PhD focused on the changes in the neuropeptide orexin (also known as hypocretin) in the hypothalamus and pons of Sudden Infant Death Syndrome (SIDS) infants. These studies demonstrated both a decline in orexin expression in aging and impairment in its expression in SIDS infants. Using a combination of animal models and proteomic study’s findings suggested that impaired orexin expression was due to an ER stress pathway. This body of work recently drew media attention both in Australia and abroad. Nicholas has worked within the Bosch and Kolling Institutes in Sydney, Australia and was a pre-doctoral fellow at the European Molecular Biology Laboratory in Heidelberg, Germany.